Stevanato Cuts 2027 Outlook to Low-Single-Digit Growth, Shares Plunge 29%
STVN is trading near its 52-week low of $12.05 (11% above the low) on elevated volume (8.5× avg).
Summary
Stevanato guided 2027 growth to low single digits and said GLP-1 sales have fallen to 17-18% of revenue as one client cut syringe volumes. Shares dropped 28.57% to $14.10 on the news. William Blair downgraded the stock to Market Perform from Outperform. Separately, company officers are under investigation over possible misleading statements to investors, though no lawsuit has been filed. The guidance cut lands just two days after Q3 results showed 8% organic revenue growth to €326.1 million and a 27.2% adjusted EBITDA margin, so the demand signal from the GLP-1 client is the key change to the thesis.
At the time of this announcement, STVN was trading at $13.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $12.05 to $27.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.